Tony's Diary Package — page 1029

to study ID-19 I NIH August 4: Part of the ACTIV initiative, an NIH-supported clinical trial showed that treating moderately ill hospitalized COVID-19 patients with a full-dose blood thinner reduced their need for organ support, such as mechanical ventilation, and improved their chances of leaving the hospital. Press release Blurb: ACTIV-4 clinical trial found that a full-dose blood thinner improved outcomes for moderately ill hospitalized patients. September 15: NIH announced $470 million in funding for a nationwide study of tens of thousands of people to support research on the long-term effects of COVID-19 called the NIH REsearching COVID to Enhance Recovery (RECOVER) Initiative. Press release Blurb: NIH funded REsearching COVID to Enhance Recovery (RECOVER) Initiative to study COVID's long-term effects. Image: Can we use this image from the timeline? NIH Strategic Response to COVID-19 I NIH COVID-19 Research October 9: Brii Biosciences filed for an FDA emergency use authorization for the ACTIV-3 monoclonal therapeutic antibody combination amubarvimab/romlusevimab that demonstrated clinical effectiveness in preventing progression of disease for mild to moderate COVID-19 patients. Blurb: ACTIV-3 trial found monoclonal therapeutic antibody combination effective in preventing disease progression in mild to moderate patients. October 27: NIH announced the Independent Test Assessment Program (ITAP), which established an accelerated pathway to support FDA evaluation of tests with potential for large-scale manufacturing. The program is an extension of the NIH RADx initiative. In less than two months, the first two over-the-counter tests that went through the ITAP accelerated pathway received EUAs, contributing millions of tests per month to the domestic supply. Press Release Blurb: NIH announced ITAP, an accelerated pathway to support FDA evaluation of COVID tests. Image: https://www.shutterstock.com/image-photo/portland-usa-feb-5-2022-closeup2118748202 January 26: The NIH clinical trial on booster doses of different COVID-19 vaccines to determine the safety and efficacy of mixed vaccine regimens found that all combinations of primary and booster